Detomax

• Sedation of intubated and mechanically ventilated patients in ICU (not to exceed 24 hours)
• Sedation of non-intubated patients prior to and/or during surgical and other procedures

Dexmedetomidine is a specific and selective alpha-2 adrenoceptor agonist. By binding to presynaptic alpha-2 adrenoceptors, it inhibits the release of norepinephrine, thereby terminating the propagation of pain signals. Activation of postsynaptic alpha-2 adrenoceptors inhibits sympathetic activity, decreasing blood pressure and heart rate.

Adult - ICU Sedation: Load: 1 mcg/kg IV over 10 minutes; Maintenance: 0.2-0.7 mcg/kg/hr IV.
Adult - Procedural Sedation: Load: 1 mcg/kg IV over 10 minutes; Maintenance: 0.6 mcg/kg/hr IV (titrate 0.2-1 mcg/kg/hr).
Elderly (65+)/Fiberoptic Intubation: Load: 1 mcg/kg IV over 10 minutes; Maintenance: 0.7 mcg/kg/hr IV.

Common: Decreased blood pressure, dry mouth, bradycardia, hypotension, nausea, atrial fibrillation, agitation, hypertension.
Other: Fever, hyperpyrexia, hypovolemia, myocardial infarction, headache, convulsion, abdominal pain, diarrhea, anemia, hypoglycemia, hallucination, oliguria, hypoventilation, hypoxia.

Pregnancy Category C. Dexmedetomidine may be unsafe during pregnancy. Animal studies have shown harmful effects on the developing baby.

Continuous monitoring of heart rate, blood pressure, respiratory rate, and oxygen level is required. Caution in 2nd/3rd degree AV block, uncontrolled hypotension, acute cerebrovascular disorders. Dose reduction may be required in hepatic impairment.

Overdose may lead to bradycardia, hypotension, and cardiac arrest.

Keep below 30°C temperature, away from light & moisture. Keep out of reach of children.